Home / Business and Economy / Greggs Boss: Weight Loss Drugs Impacting Bakery Sales
Greggs Boss: Weight Loss Drugs Impacting Bakery Sales
8 Jan
Summary
- Greggs CEO notes appetite suppressants affect sales, driving demand for healthier options.
- The bakery introduced smaller portions and protein-rich products to cater to new trends.
- Greggs reported a 7.4% total sales jump in the last quarter despite market challenges.
Greggs' chief executive, Roisin Currie, has stated that appetite-suppressing medications are undoubtedly impacting the bakery chain's business. She noted a clear consumer shift towards smaller portions and an interest in nutritional information regarding protein and fiber content. This trend is prompting Greggs to adjust its offerings to meet these evolving customer preferences.
Currie clarified that while the rise of GLP-1 medications, known for suppressing appetite, is a factor, it aligns with a broader societal health trend. To capitalize on this, Greggs has introduced new healthier products, selling half a million egg pots since their autumn launch and recently adding an overnight oats option. Despite these shifts, hot snacks also remain popular, with 1.3 million hot food items sold weekly on average.
Greggs announced a 7.4% increase in total sales for the three months ending December 27, 2025. However, full-year like-for-like sales growth was 2.4%, less than half of the previous year's rate. The growing prevalence of weight loss medications presents a significant challenge for the food industry, as users tend to consume less and seek healthier alternatives. Other major food retailers, like Tesco and M&S, are also closely monitoring these consumer behaviors and adapting their product ranges accordingly.
